S&P 500   5,061.82 (-1.20%)
DOW   37,735.11 (-0.65%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
S&P 500   5,061.82 (-1.20%)
DOW   37,735.11 (-0.65%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
S&P 500   5,061.82 (-1.20%)
DOW   37,735.11 (-0.65%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
S&P 500   5,061.82 (-1.20%)
DOW   37,735.11 (-0.65%)
QQQ   431.06 (-1.65%)
AAPL   172.69 (-2.19%)
MSFT   413.64 (-1.96%)
META   500.23 (-2.28%)
GOOGL   154.86 (-1.82%)
AMZN   183.00 (-1.68%)
TSLA   161.48 (-5.59%)
NVDA   860.01 (-2.48%)
AMD   160.32 (-1.81%)
NIO   3.89 (-5.35%)
BABA   70.62 (-0.94%)
T   16.24 (-0.43%)
F   12.23 (-3.01%)
MU   121.37 (-0.94%)
GE   153.70 (-0.60%)
CGC   6.98 (-10.51%)
DIS   112.95 (-0.93%)
AMC   2.47 (-6.79%)
PFE   25.91 (+0.19%)
PYPL   63.51 (-1.67%)
XOM   119.68 (-0.57%)
NASDAQ:OLMA

Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis

$10.85
-0.01 (-0.09%)
(As of 04:00 PM ET)
Today's Range
$10.73
$11.34
50-Day Range
$10.51
$16.62
52-Week Range
$3.55
$17.79
Volume
676,249 shs
Average Volume
798,435 shs
Market Capitalization
$606.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.43

Olema Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
97.3% Upside
$21.43 Price Target
Short Interest
Bearish
14.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.10mentions of Olema Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$835,400 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.34) to ($2.55) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

610th out of 928 stocks

Pharmaceutical Preparations Industry

286th out of 434 stocks

OLMA stock logo

About Olema Pharmaceuticals Stock (NASDAQ:OLMA)

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

OLMA Stock Price History

OLMA Stock News Headlines

Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Up 4.6%
Forget Nvidia, buy this A.I. Stock Now
Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.
OLMA Jul 2024 12.500 call
OLMA Apr 2024 22.500 call
OLMA Oct 2024 25.000 call
OLMA Oct 2024 10.000 put
OLMA Mar 2024 20.000 call
OLMA Mar 2024 10.000 put
See More Headlines
Receive OLMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/11/2024
Today
4/15/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OLMA
Fax
N/A
Employees
74
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.43
High Stock Price Target
$28.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+97.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-96,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.61 per share

Miscellaneous

Free Float
42,775,000
Market Cap
$607.29 million
Optionable
Optionable
Beta
2.10
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Sean P. Bohen M.D. (Age 57)
    Ph.D., President, CEO & Director
    Comp: $1M
  • Mr. Shane William Charles Kovacs M.B.A. (Age 50)
    Chief Operating & Financial Officer
    Comp: $726.17k
  • Dr. Naseem Zojwalla M.D. (Age 51)
    Chief Medical Officer
    Comp: $775.48k
  • Mr. Geoffrey Mogilner
    Vice President of Investor Relations & Communications
  • Ms. Julie Dexter
    Senior VP & Head of People
  • Dr. David C. Myles Ph.D. (Age 61)
    Chief Discovery & Non-Clinical Development Officer
    Comp: $200k
  • Ms. Demiana Faltaos Ph.D.
    Pharm.D., VP & Head of Clinical Pharmacology
  • Mr. John B. Moriarty Jr. (Age 56)
    J.D., Corporate Secretary
    Comp: $434.32k
  • Ms. Sasha Austin CPA
    VP of Finance & Controller

OLMA Stock Analysis - Frequently Asked Questions

Should I buy or sell Olema Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OLMA shares.
View OLMA analyst ratings
or view top-rated stocks.

What is Olema Pharmaceuticals' stock price target for 2024?

8 Wall Street analysts have issued 12-month price objectives for Olema Pharmaceuticals' stock. Their OLMA share price targets range from $18.00 to $28.00. On average, they anticipate the company's stock price to reach $21.43 in the next year. This suggests a possible upside of 97.3% from the stock's current price.
View analysts price targets for OLMA
or view top-rated stocks among Wall Street analysts.

How have OLMA shares performed in 2024?

Olema Pharmaceuticals' stock was trading at $14.03 at the start of the year. Since then, OLMA stock has decreased by 22.6% and is now trading at $10.86.
View the best growth stocks for 2024 here
.

Are investors shorting Olema Pharmaceuticals?

Olema Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 8,100,000 shares, an increase of 60.1% from the March 15th total of 5,060,000 shares. Based on an average daily trading volume, of 822,200 shares, the days-to-cover ratio is currently 9.9 days.
View Olema Pharmaceuticals' Short Interest
.

When is Olema Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our OLMA earnings forecast
.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) posted its earnings results on Monday, March, 11th. The company reported ($0.49) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.49).

When did Olema Pharmaceuticals IPO?

Olema Pharmaceuticals (OLMA) raised $170 million in an initial public offering on Thursday, November 19th 2020. The company issued 10,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OLMA) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners